Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,517 across all filing types
Latest filing 2024-10-31 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
PROFIT WARNING
Regulatory Filings Classification · 95% confidence The document is titled 'PROFIT WARNING' and is an announcement made pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions. It provides a preliminary assessment of the unaudited consolidated management accounts for the nine months ended 30 September 2024, indicating an expected decrease in profit. The document explicitly states that the quarterly results have not been finalized and that the announcement is based on preliminary unaudited data. It also advises shareholders to wait for the official quarterly results announcement expected around 15 November 2024. The document is not a full financial report but a profit warning announcement based on preliminary data. It does not contain actual financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). It is also not a simple notification of report publication (RPA) because it contains substantive preliminary financial information and analysis. Given the nature of the document as a profit warning announcement with preliminary financial data, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2024-10-31 English
VOLUNTARY ANNOUNCEMENT - FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS FURTHER CLINICAL TRIAL APPROVAL FOR NEW INDICATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial for a new indication of their CAR-T cell injection product. It discusses the product, its clinical trial approval, and its potential therapeutic benefits. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management changes, and no earnings data. The document is an announcement of a clinical trial approval, which is a regulatory update but does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention any report being published or attached. The content is primarily a regulatory announcement about clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-10-25 English
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Interim / Quarterly Report Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding the unaudited financial information of its subsidiary, CSPC Innovation Pharmaceutical Co., Ltd., for the nine months ended 30 September 2024. It references the publication of the subsidiary's third quarterly report on the Shenzhen Stock Exchange website and provides key financial data extracted from that report. The document includes detailed financial figures and analysis for the nine-month period, indicating it contains substantive financial data rather than merely announcing the report's availability. The length of the document (7416 characters) and the inclusion of financial tables and explanations confirm it is a financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-23 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and cancellations. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases and cancellations with dates and prices. The document is a regulatory disclosure about share repurchase activities and changes in capital structure, not a full financial report or earnings release. It is not an announcement of a report publication but a formal regulatory filing about share transactions. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2024-10-15 English
VOLUNTARY ANNOUNCEMENT - OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the marketing approval of a drug product by the National Medical Products Administration (NMPA) in China. It is an announcement of a regulatory milestone rather than a financial report, management change, or shareholder meeting material. The document is relatively short (2883 characters) and does not contain financial data, earnings, or detailed report content. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category about product approval. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-10-08 English
VOLUNTARY ANNOUNCEMENT - CPO301 RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the FDA granting Fast Track Designation to their drug CPO301. It is an announcement about a regulatory development related to the company's drug pipeline, not a financial report, management change, or shareholder meeting material. The document is relatively short (2561 characters) and does not contain financial data, earnings, or detailed management discussion. It is a regulatory announcement about a clinical development milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.